Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5.
Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5.
复制标题
DOI：
10.1016/j.ejca.2015.07.026
复制
发表时间：
2015-10
期刊：
影响因子：
--
通讯作者：
EUROCARE-5 Working Group:
中科院分区：
文献类型：
--
作者：
Anderson LA;Tavilla A;Brenner H;Luttmann S;Navarro C;Gavin AT;Holleczek B;Johnston BT;Cook MB;Bannon F;Sant M;EUROCARE-5 Working Group:
EUROCARE-4研究报告了1995 - 1999年诊断的患者的癌症存活率的欧洲区域差异。这里更新了2000年至2007年诊断患有食道癌、胃癌和小肠癌的患者的相对生存率（RS）估计值。从1999 - 2001年到2005 - 2007年的RS趋势，以监测和讨论欧洲患者生存率的改善。来自29个国家（87个癌症登记中心）的EUROCARE-5数据用于研究1年和5年RS。使用按年龄、性别和日历年分层的登记特定生命表，计算了北方、南方、东欧和中欧以及爱尔兰和英国（UK）按国家和地区的年龄标准化"完整分析" RS估计值。使用"周期" RS方法研究了1999 - 2001年、2002 - 2004年和2005 - 2007年期间患者的生存趋势。我们计算了5年RS条件生存的第一年（5年条件生存），作为年龄标准化的5年RS与1年RS的比值。在欧洲，食管癌1年和5年RS（分别为40%和12%）仍然较差。东欧（8%）、北方（11%）和南欧（10%）的患者生存率最差。在欧洲范围内，2005 - 2007年食管癌5年生存率提高了3%，其中爱尔兰和英国（3%）以及中欧（4%）显示出较大的改善。在欧洲范围内，胃癌5年RS为25%。爱尔兰和英国（17%）和东欧（19%）的5年患者生存率最低。南欧的5年生存率最高（30%），但在2005 - 2007年仅提高了2%。欧洲的小肠癌5年RS为48%，中欧最好（54%），爱尔兰和英国最差（37%）。2005 - 2007年，欧洲患者的5年生存率提高了8%，中欧、南欧和东欧的提高幅度最大（≥ 9%）。这些癌症部位的生存率，特别是食管癌，在欧洲仍然很低，差异很大。对广泛变化的进一步研究，包括组织学和解剖子部位的分析，将产生更好的监测和解释随着时间的推移观察到的生存改善的见解。
European regional variation in cancer survival was reported in the EUROCARE-4 study for patients diagnosed in 1995–1999. Relative survival (RS) estimates are here updated for patients diagnosed with cancer of the oesophagus, stomach, and small intestine from 2000 to 2007. Trends in RS from 1999–2001 to 2005–2007 are presented to monitor and discuss improvements in patient survival in Europe. EUROCARE-5 data from 29 countries (87 cancer registries) were used to investigate 1-and 5-year RS. Using registry-specific life-tables stratified by age, gender, and calendar year, age-standardised ‘complete analysis’ RS estimates by country and region were calculated for Northern, Southern, Eastern and Central Europe, and for Ireland and United Kingdom (UK). Survival trends of patients in periods 1999–2001, 2002–2004, and 2005–2007 were investigated using the ‘period’ RS approach. We computed the 5-year RS conditional on surviving the first year (5-year conditional survival), as the ratio of age-standardised 5-year RS to 1-year RS. Oesophageal cancer 1- and 5-year RS (40% and 12%, respectively) remained poor in Europe. Patient survival was worst in Eastern (8%), Northern (11%), and Southern Europe (10%). Europe-wide, there was a 3% improvement in oesophageal cancer 5-year survival by 2005–2007, with Ireland and the UK (3%), and Central Europe (4%) showing large improvements. Europe-wide, stomach cancer 5-year RS was 25%. Ireland and UK (17%) and Eastern Europe (19%) had the poorest 5-year patient survival. Southern Europe had the best 5-year survival (30%), though only showing an improvement of 2% by 2005–2007. Small intestine cancer 5-year RS for Europe was 48%, with Central Europe having the best (54%), and Ireland and UK the poorest (37%). Five-year patient survival improvement for Europe was 8% by 2005–2007, with Central, Southern, and Eastern Europe showing the greatest increases (≥9%). Survival for these cancer sites, particularly oesophageal cancer, remains poor in Europe with wide variation. Further investigation into the wide variation, including analysis by histology and anatomical sub-site, will yield insight to better monitor and explain the improvements in survival observed over time.
登录
查看更多内容
影响因子：
2.3
作者：
Haselkorn, T;Whittemore, AS;Lilienfeld, DE
通讯作者：
Lilienfeld, DE
影响因子：
3.1
作者：
Klint, Asa;Engholm, Gerda;Bray, Freddie
通讯作者：
Bray, Freddie
影响因子：
8.4
作者：
Baili, Paolo;Di Salvo, Francesca;Francisci, Silvia
通讯作者：
Francisci, Silvia
影响因子：
50.5
作者：
Castro, C.;Bosetti, C.;Lunet, N.
通讯作者：
Lunet, N.
影响因子：
8.8
作者：
Forbes, L. J. L.;Simon, A. E.;Wardle, J.
通讯作者：
Wardle, J.